Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Behavioural and psychological symptoms of dementia

Medicine of older adults · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Immediate danger or acute medical change

Violence, self-harm, fire or wandering danger, inability to receive essential care, sudden altered arousal or possible abuse requires urgent safety and medical assessment; acute behaviour is often delirium, pain or environmental threat.

Action: Make the setting safe, use calm de-escalation and familiar support, perform ABCDE, glucose, 4AT and pain and unmet-need review, treat causes, assess capacity and safeguarding and obtain senior mental-health or emergency help when danger persists.

Synopsis

Interpret agitation, aggression, psychosis, wandering, apathy and sleep disturbance as communication requiring trigger assessment, use personalised non-drug care first, protect carers and restrict antipsychotics to severe distress or harm with explicit review and stop plans.

  • BPSD is a descriptive umbrella, not a cause: define the exact behaviour, onset, setting, antecedent, consequence and effect on the person.
  • First-line assessment is ABCDE and 4AT when acute, then pain, bowel, bladder, infection, medicines, senses, sleep, mood, environment and safeguarding.
  • Ask carers what is new, what happens immediately before and what has previously settled the person; obtain the person's perspective with communication support.
  • First-line treatment is personalised non-drug care: meet needs, adapt communication and routine, meaningful activity, sensory support, sleep and carer coaching.
  • Do not use antipsychotics for wandering, calling out, insomnia, staff convenience or behaviour without severe distress or harm risk.
  • NICE restricts antipsychotics to risk of harm or agitation, hallucination or delusion causing severe distress after causes and non-drug care are addressed.
  • Discuss increased stroke and mortality risk, choose the lowest dose for the shortest time and document target, capacity or best interests and stop date.
  • Risperidone has a narrow short-term licence for persistent aggression in moderate-to-severe Alzheimer disease, generally no longer than six weeks.
  • Avoid haloperidol in Parkinson disease and DLB; review all antipsychotics at least every six weeks and stop when no clear ongoing benefit.
  • Support and safeguard carers without making them responsible for delivering an unsafe plan or tolerating violence.

Key red flags

Hours-to-days behaviour change, drowsiness or inattention is delirium until assessed, not a new BPSD baseline.

Pain, retention, constipation, hunger, thirst, hypoxia, infection and medicine toxicity must be checked before psychotropic treatment.

Hallucinations with parkinsonism, fluctuation or REM-sleep behaviour suggests DLB and potentially fatal antipsychotic sensitivity.

Suicide intent, weapons, serious assault, fire-setting or unsafe wandering requires an immediate risk and safeguarding plan.

Bruising, fear of a carer, overmedication or reciprocal violence requires private enquiry and adult-safeguarding consideration.

Antipsychotic sedation, rigidity, dysphagia, stroke symptoms, fever or falls requires urgent review and usually cessation.

Acute behavioural change

New behaviour with inattention or arousal change is delirium until assessed.

Safeguarding dyad

Carer and person are both frightened, injured or overwhelmed, creating immediate reciprocal risk.

Investigation priorities

01
ABC and 4AT when acuteFirst step

Detect delirium and instability. within a safe older-adult assessment.

Management branches

First-line formulationName behaviour, trigger and need

A new or recurring behavioural symptom causes concern.

  1. Treat acute physiology and delirium and obtain collateral on baseline, onset and exact episodes.
  2. Assess pain, unmet need, medicines, mood, senses, environment, communication, carer and safeguarding.
  3. Agree one personalised non-drug intervention with a target and review point.

Key medicines

RisperidoneFor its narrow licensed context, start 0.25 mg orally twice daily; increase by 0.25 mg twice daily no more often than alternate days, usually to 0.5 mg twice daily and at most 1 mg twice daily, for no longer than six weeks.Discuss stroke and mortality, check Parkinson or DLB, posture, QT and interactions and monitor sedation, falls, rigidity, swallow and infection; stop without clear benefit.
HaloperidolIf its narrow licence and local specialist protocol apply, use the smallest geriatric dose for the shortest possible course after ECG and electrolyte assessment.Contraindicated in Parkinson disease and DLB; monitor QT, extrapyramidal effects, dysphagia, neuroleptic malignant syndrome, stroke and mortality and avoid routine continuation.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG97 dementia recommendationsStructured cause assessment, non-drug care and antipsychotic threshold.
  • MHRA antipsychotic prescribing initiativeStroke, mortality and prescribing-reduction safety.
  • NICE CG103 delirium recommendationsAcute behavioural change and delirium treatment.
  • Mental Capacity Act Code of PracticeCapacity, best interests and least restriction.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom